Hubert Reyes, MD
Family Medicine · Evansville, INNPI 1497957526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,312 of the $17,576 with a category attached, or 64.4%. 50 manufacturers reported payments, led by Pfizer at 37.2% of the total. Reporting peaked in 2021 at $6,390 and has fallen 67.6% since, to $2,070 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- AbbVie$2K
- Amgen$1K
- GSK$863
- AstraZeneca$854
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$733
- plus $6K from 44 others
Across 594 payments — averaging $5455.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$668K
- GSK$553K
- Boehringer Ingelheim$513K
- Johnson & Johnson$303K
- Amgen$276K
- AbbVie$186K
- plus $741K from 17 others
What the payments were for
- Consulting fees$6,17535%
- Food & beverage$11,31264%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,576 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 86 | $84,697 |
| OzempicSemaglutide | 78 | $79,849 |
| EliquisApixaban | 87 | $78,802 |
| JardianceEmpagliflozin | 52 | $55,335 |
| RybelsusSemaglutide | 43 | $50,095 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $48,370 |
| FarxigaDapagliflozin Propanediol | 48 | $44,235 |
| JanuviaSitagliptin Phosphate | 29 | $41,258 |
| VascepaIcosapent Ethyl | 82 | $38,681 |
| MounjaroTirzepatide | 24 | $37,798 |
| MyrbetriqMirabegron | 25 | $31,009 |
| LinzessLinaclotide | 43 | $25,779 |
| VraylarCariprazine Hcl | 16 | $24,748 |
| TrulicityDulaglutide | 16 | $24,689 |
| EntrestoSacubitril/Valsartan | 27 | $22,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $471 | $129,944121 claims |
| Johnson & JohnsonXarelto | $435 | $84,69786 claims |
| PfizerEliquis | $6,539 | $78,80287 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $196 | $66,35067 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $863 | $63,00781 claims |
| Lilly USA, LLCMounjaro, Trulicity | $373 | $62,48840 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $854 | $60,84175 claims |
| AbbVieLinzess, Vraylar | $1,707 | $50,52759 claims |
| MerckJanuvia | $78 | $41,25829 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $31,00925 claims |
| NovartisEntresto | $413 | $22,87727 claims |
| Axsome Therapeutics, Inc.Auvelity | $412 | $21,05119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- Anthony InzerelloEvansville$308K
- Carol GoodmanEvansville$123K
- David SchultzEvansville$22K
- J Christopher SartoreEvansville$19K
- David BrougherEvansville$18K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.